While there is clear cardiovascular risk reduction associated with GLP-1 RA use in patients with T2DM and CKD, the proof of benefit on renal outcome will come with the results of the ongoing FLOW (A Research Study to See How Semaglutide Works Compared with Placebo in People With Type 2 Diabetes and Chronic Kidney Disease) trial with injectable semaglutide [82]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.